Two linear OCT slices of the same eye with (C) and without (D ... Visual field defects and changes in macular retinal ...

Ijeoma Uchegbu discusses nanomedicine's role in improving medication adherence and developing non-addictive pain relief ...

In the deal, Nippon Shinyaku can exclusively sell ATSN-101 in the US and develop and sell it in Japan, while Atsena retains rights to other territories.

That is: building a global community and developing unique, innovative products that set it apart from competitors, like its ...